GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (HKSE:02500) » Definitions » Forward PE Ratio

Venus Medtech (Hangzhou) (HKSE:02500) Forward PE Ratio : 0.00 (As of Sep. 25, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Venus Medtech (Hangzhou) Forward PE Ratio?

Venus Medtech (Hangzhou)'s Forward PE Ratio for today is 0.00.

Venus Medtech (Hangzhou)'s PE Ratio without NRI for today is 0.00.

Venus Medtech (Hangzhou)'s PE Ratio for today is 0.00.


Venus Medtech (Hangzhou) Forward PE Ratio Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Forward PE Ratio Chart

Venus Medtech (Hangzhou) Annual Data
Trend 2020-12 2021-12 2022-04
Forward PE Ratio
80.00 125.00 34.72

Venus Medtech (Hangzhou) Semi-Annual Data
2020-03 2020-06 2020-09 2020-12 2021-03 2021-06 2021-09 2021-12 2022-03
Forward PE Ratio 144.93 270.27 73.53 80.00 57.47 322.58 163.93 125.00 35.46

Competitive Comparison of Venus Medtech (Hangzhou)'s Forward PE Ratio

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Venus Medtech (Hangzhou)'s Forward PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Forward PE Ratio falls into.



Venus Medtech (Hangzhou) Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Venus Medtech (Hangzhou)  (HKSE:02500) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Venus Medtech (Hangzhou) Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Venus Medtech (Hangzhou) Business Description

Traded in Other Exchanges
N/A
Address
No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051
Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.
Executives
Zeng Min Frank 2201 Interest of corporation controlled by you
Zi Zhenjun 2201 Interest of corporation controlled by you
Ming Zhi Investments (bvi) Limited 2101 Beneficial owner
Ming Zhi Investments Limited 2201 Interest of corporation controlled by you
Qiming Venture Partners Iii, L.p. 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iii, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iii, L.p. 2201 Interest of corporation controlled by you
Dcp Capital Partners, L.p. 2201 Interest of corporation controlled by you
Dcp General Partner, Ltd 2201 Interest of corporation controlled by you
Dcp, Ltd. 2201 Interest of corporation controlled by you
Liu Haifeng David 2201 Interest of corporation controlled by you
Muheng Capital Partners (hong Kong) Limited 2101 Beneficial owner
Red Giant Limited 2201 Interest of corporation controlled by you
Wolhardt Julian Juul 2201 Interest of corporation controlled by you
Horizon Binjiang Llc 2101 Beneficial owner

Venus Medtech (Hangzhou) Headlines

No Headlines